Thsi section focuses on the evolving landscape of CAR-T cell therapy for multiple myeloma, particularly BCMA-targeted treatments and next-generation cellular therapies. We share updates on clinical trials, long-term remission data, combination strategies, and access pathways in China and worldwide. Stay informed on how CAR-T is transforming treatment options for relapsed or refractory multiple myeloma.
A 65-center Chinese real-world analysis presented at IMS 2026 reports deep responses with Eque-cel across older, heavily pretreated and high-risk RRMM patients.
Bristol Myers Squibb’s GPRC5D-directed CAR-T therapy arlo-cel has met the key efficacy endpoints of the Phase 2 QUINTESSENTIAL trial in heavily pretreated multiple myeloma. The results could be particularly important for patients whose disease has progressed after BCMA-directed treatment.
OL-101, a novel BCMA/GPRC5D dual-target CAR-T cell therapy, achieved 100% ORR and deep responses in a Phase I study of heavily pretreated R/R multiple myeloma patients, including those with prior CAR-T exposure and extramedullary disease, presented at EHA 2026.
CAR-T cell therapy, antibody-drug conjugates (ADCs), and bispecific antibodies are transforming the treatment landscape for multiple myeloma. Discover how these innovative immunotherapies work and the benefits they offer patients with relapsed or refractory disease.
As CAR-T therapy reshapes treatment for multiple myeloma worldwide, China is emerging as a key alternative with strong research, lower costs, and faster access.
At ASH 2025, IASO Bio presented updated FUMANBA-2 data for equecabtagene autoleucel in high-risk newly diagnosed multiple myeloma, with a 100% ORR, 93.8% sCR rate and 74.5% 24-month PFS.
On November 3, new clinical data were released for a universal BCMA-targeted CAR-T therapy candidate (CT0596) in patients with relapsed/refractory multiple myeloma (R/R MM). The results show favorable preliminary safety
Multiple myeloma (MM), a malignant plasma cell disorder, continues to pose major treatment challenges for patients with relapsed or refractory disease (R/R MM), despite continuous advances in therapeutic options. While
Eque-cel CAR-T Therapy Shows Durable Efficacy and Strong Safety Profile in Heavily Pretreated Multiple Myeloma Patients
Long-term follow-up results from the Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, an autologous CAR T-cell product targeting BCMA) were recently presented as a poster at the 22nd International
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.